180 related articles for article (PubMed ID: 31665821)
1. Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.
Wood EA; Lu Z; Jia S; Assumpção ALFV; Van Hesteren MA; Huelsmeyer MK; Vail DM; Pan X
Vet Comp Oncol; 2020 Sep; 18(3):269-280. PubMed ID: 31665821
[TBL] [Abstract][Full Text] [Related]
2. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
4. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
5. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
7. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
8. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
9. Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.
Olaverria Salavaggione GN; Duggan MC; Carson WE
Melanoma Res; 2018 Oct; 28(5):390-397. PubMed ID: 30020196
[TBL] [Abstract][Full Text] [Related]
10. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
11. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A
Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
[TBL] [Abstract][Full Text] [Related]
13. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
[TBL] [Abstract][Full Text] [Related]
14. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
[TBL] [Abstract][Full Text] [Related]
15. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
[TBL] [Abstract][Full Text] [Related]
17. The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.
El-Mesery M; Anany MA; Hazem SH; Shaker ME
Arch Biochem Biophys; 2020 Sep; 691():108513. PubMed ID: 32721435
[TBL] [Abstract][Full Text] [Related]
18. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis.
Wu MH; Lee CY; Huang TJ; Huang KY; Tang CH; Liu SH; Kuo KL; Kuan FC; Lin WC; Shi CS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586948
[TBL] [Abstract][Full Text] [Related]
19. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
[TBL] [Abstract][Full Text] [Related]
20. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.
Zhang Y; Shi CC; Zhang HP; Li GQ; Li SS
Oncotarget; 2016 Jul; 7(29):45263-45274. PubMed ID: 27223074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
